1-<2-(3-nitrophenoxy)ethyl>-1H-imidazole | 112677-69-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-<2-(3-nitrophenoxy)ethyl>-1H-imidazole
• 英文别名: 1-[2-(3-Nitrophenoxy)ethyl]-1H-imidazole；1-[2-(3-nitrophenoxy)ethyl]imidazole
• CAS: 112677-69-7
• 化学式: C₁₁H₁₁N₃O₃
• 分子量: 233.227
• InChiKey: WITOOSRPFRQFRJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  72.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-<2-(3-nitrophenoxy)ethyl>-1H-imidazole 在 platinum(IV) oxide 盐酸 、 氢气 作用下， 以 乙醇 为溶剂， 反应 0.25h， 生成 N-[3-(2-Imidazol-1-yl-ethoxy)-phenyl]-guanidine; hydrochloride
  参考文献：
  名称：

  Preparation of substituted N-phenyl-4-aryl-2-pyrimidinamines as mediator release inhibitors

  摘要：

  The role of immunologically released mediators, such as histamine, leukotrienes, and platelet-activating factor, is well-established for asthma and other allergic disorders. Developing therapeutic agents which would block mediator release from mast cells and other relevant cell types would provide a rational approach to asthma therapy. Using human basophil as a screen, a series of 4-aryl-2-(phenylamino)pyrimidines was found which inhibited mediator release. These compounds were prepared by condensing acetyl heterocycles with dimethylformamide dimethyl acetal to form enaminones which are cyclized with aryl guanidines to give pyrimidines. After examining a large number of analogs, N-[3-(1H-imidazol-1-yl)phenyl]-4-(2-pyridinyl)-2-pyrimidinamine (1-27) was chosen for toxicological evaluation.

  DOI：

  10.1021/jm00071a002
• 作为产物：
  描述：

  咪唑 、 1-(2-溴乙氧基)-3-硝基苯 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 1-<2-(3-nitrophenoxy)ethyl>-1H-imidazole
  参考文献：
  名称：

  Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors

  摘要：

  We designed a series of anilino-indoylmaleimides based on structural elements from literature JAK3 inhibitors 3 and 4, and our lead 5. These new compounds were tested as inhibitors of JAKs 1, 2 and 3 and TYK2 for therapeutic intervention in rheumatoid arthritis (RA). Our requirements, based on current scientific rationale for optimum efficacy against RA with reduced side effects, was for potent, mixed JAK1 and 3 inhibition, and selectivity over JAK2. Our efforts yielded a potent JAK3 inhibitor 11d and its eutomer 11e. These compounds were highly selective for inhibition of JAK3 over JAK2 and TYK. The compounds displayed only modest JAK1 inhibition. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.01.001

文献信息

• 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines
  申请人：American Cyanamid Company

  公开号：US04788195A1

  公开（公告）日：1988-11-29

  This disclosure describes novel 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines having anti-asthmatic activity.

  这份披露描述了具有抗哮喘活性的新型4,5,6-取代-N-(取代苯基)-2-嘧啶胺。
• 4,5,6-Substituted-2-pyrimidinamines
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0233461A2

  公开（公告）日：1987-08-26

  This disclosure describes novel 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines having anti-asthmatic activity.

  本公开介绍了具有抗哮喘活性的新型 4,5,6-取代-N-（取代苯基）-2-嘧啶胺。
• US4788195A
  申请人：——

  公开号：US4788195A

  公开（公告）日：1988-11-29
• US4876252A
  申请人：——

  公开号：US4876252A

  公开（公告）日：1989-10-24
• US5708171A
  申请人：——

  公开号：US5708171A

  公开（公告）日：1998-01-13